- Trials with a EudraCT protocol (352)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
352 result(s) found for: First impression.
Displaying page 9 of 18.
EudraCT Number: 2016-000281-39 | Sponsor Protocol Number: CEMA401A2202 | Start Date*: 2018-03-08 | |||||||||||
Sponsor Name:Novartis Pharma AG | |||||||||||||
Full Title: A double-blind, placebo-controlled, randomized trial to determine the safety and efficacy of EMA401 in reducing 24-hour average pain intensity score in patients with painful diabetic neuropathy (EM... | |||||||||||||
Medical condition: Painful Diabetic Neuropathy | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NO (Completed) GB (Prematurely Ended) HU (Completed) ES (Prematurely Ended) DK (Prematurely Ended) BE (Completed) SK (Prematurely Ended) FI (Prematurely Ended) DE (Prematurely Ended) AT (Prematurely Ended) PT (Prematurely Ended) BG (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-003342-15 | Sponsor Protocol Number: F1D-MC-HGMT | Start Date*: 2007-12-05 |
Sponsor Name:Eli Lilly and Company Limited | ||
Full Title: A Randomized, Open-Label Study Comparing the Effectiveness of Olanzapine Pamoate Depot with Haloperidol Decanoate in the Treatment of Schizophrenia | ||
Medical condition: Schizophrenia | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: HU (Prematurely Ended) FR (Completed) GB (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2019-004497-25 | Sponsor Protocol Number: 18898A | Start Date*: 2020-10-27 | |||||||||||
Sponsor Name:H. Lundbeck A/S | |||||||||||||
Full Title: Interventional, randomized, double-blind, parallel-group, placebo-controlled study with an extension period to evaluate the efficacy and safety of eptinezumab for the prevention of migraine in pati... | |||||||||||||
Medical condition: Migraine in patients with unsuccessful prior preventive treatments | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) CZ (Completed) DK (Completed) FI (Completed) BE (Completed) PL (Completed) GB (GB - no longer in EU/EEA) SK (Completed) HU (Completed) SE (Completed) BG (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-003051-19 | Sponsor Protocol Number: Z7190M01 | Start Date*: 2012-02-14 | |||||||||||
Sponsor Name:ZAMBON S.p.A. | |||||||||||||
Full Title: Evaluation of the speed of action of Ibuprofen Arginine in comparison to Ibuprofen in the acute pain relief after mini invasive orthopaedic arthroscopic knee surgery in adults. | |||||||||||||
Medical condition: Postoperative acute pain. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-005808-17 | Sponsor Protocol Number: HEEL-2012-04 | Start Date*: 2013-06-11 | ||||||||||||||||
Sponsor Name:Radboud University Medical Centre | ||||||||||||||||||
Full Title: The analgesic efficacy of perioperative Δ9-THC (Namisol®) in patients undergoing major abdominal surgery: a randomized, double blinded, placebo-controlled, parallel design | ||||||||||||||||||
Medical condition: Patients undergoing elective major abdominal surgery | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: NL (Prematurely Ended) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-005490-20 | Sponsor Protocol Number: 2002C011G | Start Date*: 2016-06-29 | |||||||||||
Sponsor Name:ProMetic BioTherapeutics Inc. | |||||||||||||
Full Title: A Phase 2/3, Open-Label, Repeat-Dose Study of the Pharmacokinetics, Efficacy, and Safety of ProMetic Plasminogen Intravenous Infusion in Subjects with Hypoplasminogenemia | |||||||||||||
Medical condition: Hypoplasminogenemia | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NO (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-020718-26 | Sponsor Protocol Number: WN25305 | Start Date*: 2011-01-24 | |||||||||||
Sponsor Name:F. Hoffmann-La Roche Ltd | |||||||||||||
Full Title: Phase III, multi-center, randomized, 12-week, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy and safety of RO4917838 in patients with sub-optimally controlled sympt... | |||||||||||||
Medical condition: Adjunctive treatment of patients with sub-optimally controlled symptoms of schizophrenia. Sub-optimally controlled patients are defined as those who on their current medication have persistent symp... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) IT (Prematurely Ended) BG (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-005475-40 | Sponsor Protocol Number: VP-VEC-162-3502 | Start Date*: 2022-06-08 | |||||||||||
Sponsor Name:Vanda Pharmaceuticals Inc. | |||||||||||||
Full Title: A multicenter, double-blind, randomized study to evaluate the effects of tasimelteon vs. placebo in participants with Delayed Sleep-Wake Phase Disorder (DSWPD) | |||||||||||||
Medical condition: Delayed Sleep-Wake Phase Disorder (DSWPD) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Trial now transitioned) AT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-001040-35 | Sponsor Protocol Number: D3250C00045 | Start Date*: 2017-08-21 | ||||||||||||||||
Sponsor Name:AstraZeneca AB | ||||||||||||||||||
Full Title: A Multicenter, Randomized, Double-blind, Parallel Group, Placebo controlled, Phase 3b Study to Evaluate the Safety and Efficacy of Benralizumab 30 mg sc in Patients with Severe Asthma Uncontrolled ... | ||||||||||||||||||
Medical condition: severe uncontrolled asthma | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DK (Completed) GB (Completed) FR (Completed) BE (Completed) SE (Completed) NL (Completed) AT (Completed) ES (Completed) FI (Completed) IT (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2006-006291-38 | Sponsor Protocol Number: 06-010 | Start Date*: 2007-10-02 | |||||||||||
Sponsor Name:Jazz Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Long-Term, Open-Label Safety and Efficacy Study of Xyrem (sodium oxybate) in Subjects with Fibromyalgia | |||||||||||||
Medical condition: Fibromyalgia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) DE (Completed) FR (Ongoing) NL (Completed) PL (Completed) IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-001674-34 | Sponsor Protocol Number: AG348-C-020 | Start Date*: 2022-02-17 | |||||||||||
Sponsor Name:AGIOS PHARMACEUTICALS, INC. | |||||||||||||
Full Title: A Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Mitapivat in Subjects With Sickle Cell Disease. | |||||||||||||
Medical condition: Sickle Cell Disease | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Trial now transitioned) FR (Trial now transitioned) BE (Trial now transitioned) DE (Trial now transitioned) NL (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2004-001116-31 | Sponsor Protocol Number: ESCLIN-002/04 | Start Date*: 2004-11-03 |
Sponsor Name:Laboratorios Dr. Esteve S.A. | ||
Full Title: Multicentre, randomised, double-blind, parallel group confirmatory Phase III study to compare the efficacy and safety of cizolirtine citrate 300 mg bid (600 mg/d), cizolirtine citrate 400 mg bid (... | ||
Medical condition: Urge Urinary Incontinence | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Completed) GB (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2016-002675-97 | Sponsor Protocol Number: ONO-4474-02 | Start Date*: 2016-12-23 | |||||||||||
Sponsor Name:Ono Pharmaceutical Co., Ltd. | |||||||||||||
Full Title: A randomised, double-blind, placebo controlled, parallel group, multi-centre, study to evaluate the efficacy, safety, tolerability and pharmacokinetics of ONO-4474 in patients with pain due to oste... | |||||||||||||
Medical condition: Osteoarthritic Pain | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) DK (Prematurely Ended) ES (Completed) PL (Completed) GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-003679-31 | Sponsor Protocol Number: 2015_22 | Start Date*: 2016-04-06 |
Sponsor Name:Centre Hospitalier Régional et Universitaire de Lille | ||
Full Title: Conservative iron chelation as a disease-modifying strategy in Parkinson’s disease | ||
Medical condition: De Novo Parkinson’s disease | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Completed) ES (Ongoing) CZ (Completed) PT (Completed) FR (Completed) NL (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2016-004395-22 | Sponsor Protocol Number: 402-C-1603 | Start Date*: 2017-12-19 | |||||||||||
Sponsor Name:Reata Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Phase 2/3 Trial of the Efficacy and Safety of Bardoxolone Methyl in Patients with Alport Syndrome | |||||||||||||
Medical condition: Alport Syndrome | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) GB (GB - no longer in EU/EEA) ES (Completed) FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-005186-13 | Sponsor Protocol Number: CLNP023F12301 | Start Date*: 2021-08-26 | |||||||||||
Sponsor Name:Novartis Pharma AG | |||||||||||||
Full Title: A multicenter, single-arm, open label trial to evaluate efficacy and safety of oral, twice daily LNP023 in adult aHUS patients who are naive to complement inhibitor therapy | |||||||||||||
Medical condition: atypical hemolytic uremic syndrome | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Trial now transitioned) SI (Trial now transitioned) CZ (Trial now transitioned) SK (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-000256-33 | Sponsor Protocol Number: Ra-P-OCD-01 | Start Date*: 2019-06-27 | |||||||||||
Sponsor Name:Uppsala University Hospital | |||||||||||||
Full Title: A randomized, double-blinded, placebo-controlled study of Rituximab in patients with Psychosis and/or Obsessive Compulsive Disorder, with an indication of immune system involvement | |||||||||||||
Medical condition: Obsessive-compulsive disorder (OCD) or Obsessive-compulsive behaviour (OCB) or psychotic disorder (PD) in which there is an indication of immune system involvement. | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-002023-11 | Sponsor Protocol Number: 53718678RSV3001 | Start Date*: 2021-02-16 | |||||||||||
Sponsor Name:Janssen-Cilag International NV | |||||||||||||
Full Title: A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Rilematovir in Infants and Children (≥28 Days to ≤5 Years of Age) and Subsequently in Neonates (... | |||||||||||||
Medical condition: Respiratory Syncytial Virus | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: BG (Completed) DE (Prematurely Ended) SE (Completed) CZ (Completed) HU (Completed) BE (Completed) PL (Completed) Outside EU/EEA EE (Completed) LV (Completed) SK (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-003471-34 | Sponsor Protocol Number: REN001-202 | Start Date*: 2022-04-19 | |||||||||||
Sponsor Name:Reneo Pharma Ltd. | |||||||||||||
Full Title: AN OPEN-LABEL, MULTI-CENTRE STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF REN001 IN SUBJECTS WITH PRIMARY MITOCHONDRIAL MYOPATHY (PMM) | |||||||||||||
Medical condition: Primary Mitochondrial Myopathy | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) ES (Prematurely Ended) DK (Prematurely Ended) BE (Completed) HU (Prematurely Ended) NL (Ongoing) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-017271-17 | Sponsor Protocol Number: R092670-SCA-3004 | Start Date*: 2010-10-29 | |||||||||||
Sponsor Name:Janssen-Cilag International NV | |||||||||||||
Full Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of Paliperidone Palmitate Evaluating Time to Relapse in Subjects With Schizoaffective Disorder | |||||||||||||
Medical condition: Schizoaffective Disorder | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BG (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
